Stocklytics Platform
Asset logo for symbol NUVL
Nuvalent
NUVL41
$89.24arrow_drop_up3.46%$2.99
Asset logo for symbol NUVL
NUVL41

$89.24

arrow_drop_up3.46%
Key Stats
Open$85.26
Prev. Close$86.25
EPS-2.79
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range85.26
89.32
52 Week Range39.86
89.39
Ratios
Revenue-
EBITDA Margin %-
EPS-2.79
Fundamentals
Gross Profit-
EBITDA
Total Debt
Payout Ratio-
Industry average yield2.91%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

NUVL-
US Healthcare Sector-
US Market-
check_circle

NUVL / Market

NUVL exceeded the US Market which returned -1.02% over the last twenty four hours.
check_circle

NUVL / Healthcare Sector

NUVL exceeded the US Healthcare sector which returned -0.54% over the last twenty four hours.

Nuvalent (NUVL) Statistics

Nuvalent, Inc. (NUVL) is a pharmaceutical company specializing in the development and commercialization of novel medicines for the treatment of cancer. As of the latest available data, the stock statistics of Nuvalent, Inc. show that it is trading at a certain price in the stock market. This information can be useful for investors who are interested in evaluating the performance of the company's stock and making informed investment decisions.
When it comes to valuation metrics, Nuvalent, Inc. is valued based on various factors such as its market capitalization, earnings, and revenue. These metrics provide an indication of the company's worth in the stock market and can be used to compare it with other companies in the sector. It is important to note that valuation metrics should not be the sole factor considered when making investment decisions, as they should be analyzed in conjunction with other fundamental and qualitative factors.
add Nuvalent to watchlist

Keep an eye on Nuvalent

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Nuvalent (NUVL) stock's performance compared to its sector and the market over the past year?

Over the past year, Nuvalent (NUVL) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.88%, Nuvalent has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 61.39%, it has fallen short of the market average. This comparison highlights Nuvalent's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Nuvalent (NUVL) stock?

The PE ratio for Nuvalent (NUVL) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Nuvalent (NUVL) stock?

The Earnings Per Share (EPS) for Nuvalent (NUVL), calculated on a diluted basis, is -$2.79. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Nuvalent (NUVL) stock?

The operating margin for Nuvalent (NUVL) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Nuvalent (NUVL) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Nuvalent (NUVL) is $0. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Nuvalent (NUVL) have?

Nuvalent (NUVL) has a total debt of $0. The net debt, which accounts for cash and cash equivalents against the total debt, is -$77.7M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media